Monday that late-stage clinical trials showed its vaccine was, on average, 70 percent effective in preventing COVID-19. The effectiveness of the vaccine developed with Oxford University depended on the dose. Some of the 20,000 trial participants were given a single dose, and in those cases the vaccine was 62 percent effective.
The AstraZeneca-Oxford vaccine is the third vaccine candidate to report successful clinical trials this month, following Pfizer and Moderna’s announcements, though this latest vaccine will likely be cheaper and far easier to distribute. “While the results released by AstraZeneca indicate somewhat lower efficacy … the vaccine can be stored and transported at normal refrigerated conditions for up to six months,” the Washington Post.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.